StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.37−0.01 (-3.62%)

Close on Nov 18, 2026Market cap $7.20MP/E –Yield –

Ensysce Biosciences total assets

Total assets on the balance sheet at the end of each period.

Ensysce Biosciences's total assets was $2.96M at Jun 30, 2026. For fiscal 2025 it was $7.45M, up 33.1% from the year before. The highest annual figure on record is $204.83M in fiscal 2018.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.45M+33.1%
FY2024Dec 31, 2024$5.60M+106.7%
FY2023Dec 31, 2023$2.71M-54.0%
FY2022Dec 31, 2022$5.89M-64.2%
FY2021Dec 31, 2021$16.42M+4566.6%
FY2020Dec 31, 2020$351.81K-99.8%
FY2019Dec 31, 2019$196.51M-4.1%
FY2018Dec 31, 2018$204.83M+1.2%
FY2017Dec 31, 2017$202.43M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.96M-46.9%
Q1 FY2026Mar 31, 2026$2.17M-53.0%
Q4 FY2025Dec 31, 2025$7.45M+33.1%
Q3 FY2025Sep 30, 2025$3.18M-66.1%
Q2 FY2025Jun 30, 2025$5.57M+99.4%
Q1 FY2025Mar 31, 2025$4.61M-9.1%
Q4 FY2024Dec 31, 2024$5.60M+106.7%
Q3 FY2024Sep 30, 2024$9.38M+191.6%
Q2 FY2024Jun 30, 2024$2.80M-56.0%
Q1 FY2024Mar 31, 2024$5.07M+29.6%
Q4 FY2023Dec 31, 2023$2.71M-54.0%
Q3 FY2023Sep 30, 2023$3.22M-61.2%
Q2 FY2023Jun 30, 2023$6.36M-20.0%
Q1 FY2023Mar 31, 2023$3.91M-68.4%
Q4 FY2022Dec 31, 2022$5.89M-64.2%
Q3 FY2022Sep 30, 2022$8.29M-14.7%
Q2 FY2022Jun 30, 2022$7.95M-13.6%
Q1 FY2022Mar 31, 2022$12.37M-4.7%
Q4 FY2021Dec 31, 2021$16.42M+4566.6%
Q3 FY2021Sep 30, 2021$9.72M-26.9%
Q2 FY2021Jun 30, 2021$9.20M-31.4%
Q1 FY2021Mar 31, 2021$12.98M-78.9%
Q4 FY2020Dec 31, 2020$351.81K-99.8%
Q3 FY2020Sep 30, 2020$13.29M-93.6%
Q2 FY2020Jun 30, 2020$13.41M-93.5%
Q1 FY2020Mar 31, 2020$61.60M-70.0%
Q4 FY2019Dec 31, 2019$196.51M-4.1%
Q3 FY2019Sep 30, 2019$207.21M+1.6%
Q2 FY2019Jun 30, 2019$206.36M+1.5%
Q1 FY2019Mar 31, 2019$205.56M+1.3%
Q4 FY2018Dec 31, 2018$204.83M+1.2%
Q3 FY2018Sep 30, 2018$204.03M–
Q2 FY2018Jun 30, 2018$203.23M–
Q1 FY2018Mar 31, 2018$202.87M–
Q4 FY2017Dec 31, 2017$202.43M–

More Ensysce Biosciences figures

See a number that looks wrong?